|
Complement inhibitor | Medicine | Diseases | Study phase |
|
Recombinant C1 inhibitor | Conestat alfa | HAE Side effects: headache and allergy. | In clinical use, EU approved. |
(Ruconest in Europe/Rhucin in USA) |
|
Plasma-derived C1 inhibitors | Berinert P/cinryze | HAE | In clinical use, FDA approved. |
|
C3 inhibitors | Compstatin (POT-4) | AMD | Phase II |
Staphylococcal complement inhibitor (SCIN) | ā | Preclinical |
|
Myristoylated peptidyl derived from soluble CR1 | Mirococept (APT070) | Delayed graft function of cadaveric kidney after transplantation. | Phase II |
|
Factor H | Plasma-derived factor H concentrate | HUS, AMD | Preclinical |
TT30/targeted alternative pathway inhibitor/factor H | PNH, AMD | Phase I |
|
Factor D inhibitor | Anticomplement factor D | AMD | Phase II |
|
Factor B inhibitor | TA106/anti-complement factor B | AMD | Preclinical |
|
C5 inhibitors | Eculizumab | PNH Side effects: headache, thrombocytopenia, gastrointestinal complaints and infections. Before use: vaccination against meningococcal infection. | In clinical use, FDA approved. |
Various other diseases, for example, kidney transplants, HUS, AMD. | Phase I |
Pexelizumab | ā | Phase III study failed |
Mubodina | HUS | Preclinical |
Ergidina | Ischemia/reperfusion injury | Preclinical |
ARC 1905 | AMD | Phase I |
|
C5a inhibitor | PMX 53 and several other compounds | AMD | Phase II study discontinued |
Osteoarthritis | Phase I |
|
Targeted complement inhibitors | Targeted (CR2 mediated) complement inhibitors | Chronic glomerulonephritis | Phase I |
|